Pathophysiology of COVID-19: A Post Hoc Analysis of the ICAT-COVID Clinical Trial of the Bradykinin Antagonist Icatibant
Open Access
Abstract
We used the data from a successful therapeutic assay that used icatibant in patients with hypoxemic COVID-19 pneumonia (the ICAT·COVID trial) to explore pathophysiological mechanisms. We performed concurrent-type, criterion-related validity analyses to assess the discriminative ability of a panel of nine potential serum markers (interleukin 6, ferritin, lactate dehydrogenase, C reactive protein, fibrin fragment D (D-dimer), complement 1 esterase inhibitor (antigenic and functional), complement 4 factor, and lymphocyte count) to predict the clinical milestones. Consistent with previous research, we evidenced a significant relationship between interleukin 6, lactate dehydrogenase and the lymphocyte count, and the clinical events. Furthermore, exposure to icatibant, a bradykinin B2 receptor antagonist (which improved pneumonia and mortality in the aforementioned randomised trial), attenuated this relationship, although this effect faded over time. The results reinforce the key role that the angiotensin-converting enzyme 2 has on COVID-19 pathophysiology as a point of convergence between the renin–angiotensin and kallikrein–kinin systems. This was shown clinically by the successful blocking of inflammatory pathways by icatibant at the bradykinin effector loop level early during the acute hyperinflammatory stage of the disease.Keywords
Funding Information
- Takeda
This publication has 35 references indexed in Scilit:
- Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trialeClinicalMedicine, 2023
- Serum ferritin as a predictive biomarker in COVID-19. A systematic review, meta-analysis and meta-regression analysisJournal of Critical Care, 2021
- Biomarkers of endothelial dysfunction and outcomes in coronavirus disease 2019 (COVID-19) patients: A systematic review and meta-analysisMicrovascular Research, 2021
- COVID-19 cytokine storm: The anger of inflammationCytokine, 2020
- Interleukin‐6 in Covid‐19: A systematic review and meta‐analysisReviews in Medical Virology, 2020
- The four horsemen of a viral Apocalypse: The pathogenesis of SARS-CoV-2 infection (COVID-19)EBioMedicine, 2020
- COVID-19 pathophysiology: A reviewClinical Immunology, 2020
- Hematological findings and complications of COVID‐19American Journal of Hematology, 2020
- Bradykinin receptor‐1 activation induces inflammation and increases the permeability of human brain microvascular endothelial cellsCell Biology International, 2019
- Pleiotropy and Specificity: Insights from the Interleukin 6 Family of CytokinesImmunity, 2019